Astra Pharmaceuticals

FDA approves new MCL treatment by AstraZeneca

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.

Business Insider · 1d

AstraZeneca’s Calquence combination approved in U.S.

Calquence in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients

Seeking Alpha on MSN · 1d

AstraZeneca lymphoma therapy Calquence gets expanded approval in the U.S.

AstraZeneca (NASDAQ:AZN) announced Friday that the U.S. FDA approved its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) with chemoimmunotherapy as a first-line option for adults with mantle cell lymphoma,

AstraZeneca Pharma share price rises 3% on CDSCO nod for Eculizumab

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for ...

Zacks.com on MSN12d

AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?

AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations at its China subsidiary. However, the overall drug and biotech sector has ...

Medindia26d

Bio-Thera Solutions Partners with Tabuk Pharmaceuticals to Commercialize BAT2206, a Stelara® (Ustekinumab) Biosimilar in Saudi Arabia

Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company has partnered ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now